Kalaris Therapeutics (KLRS)
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal dis...
- Open
- 3.970
- High
- 4.040
- Low
- 3.905
- Prev. Close
- 3.900
- Volume
- 39.99K
- Turnover
- 158.65K
- Avg Price
- 3.968
- Bid/Ask Ratio
- --
- Amplitude
- 3.46%
- 52wk High
- 11.880
- Volume Ratio
- 0.17
- Turnover Ratio
- 0.55%
Kalaris Therapeutics Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$18.71374.98%
Forecast & RatingBuy
8analysts
- Strong buy62.50%
- Buy25.00%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 31 at 12:03 PM
Kalaris Therapeutics management to join Morgan Stanley Global Healthcare Conference fireside chat
- Market Beat · Aug 11 at 01:11 PM
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results
- TradingView · Aug 11 at 12:13 PM
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand
- PUBT · Aug 11 at 12:04 PM
Kalaris net loss widens to $11.52 million in Q2 FY26
- Unusual Whales · Aug 11 at 12:02 PM
Kalaris announces Q2 2026 financials, along with business updates.
